Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

deferiprone

Known as: 1,2-dimethyl-3-hydroxypyrid-4-one, DMOHPO, 1,2-dimethyl-3-hydroxypyridin-4-one 
An orally bioavailable bidentate ligand with iron chelating activity. Deferiprone binds to iron in a 3:1 (ligand:iron) molar ratio. By binding to… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
Iron chelation has been introduced as a new therapeutic concept for the treatment of neurodegenerative diseases with features of… Expand
  • figure 1
  • table 1
  • table 1
Review
2017
Review
2017
ABSTRACT Symptoms of Parkinson's disease arise due to neuronal loss in multiple brain regions, especially dopaminergic neurons in… Expand
  • figure 1
Highly Cited
2007
Highly Cited
2007
Background— Cardiac complications secondary to iron overload are the leading cause of death in &bgr;-thalassemia major… Expand
  • figure 1
  • figure 2
  • figure 4
  • figure 3
  • figure 5
Highly Cited
2006
Highly Cited
2006
Deferoxamine (DFO) therapy has been associated with improved survival of thalassemia patients. However, cardiac disease remains… Expand
  • table 1
  • figure 1
  • table 2
  • figure 2
Highly Cited
2006
Highly Cited
2006
Most deaths in beta-thalassemia major result from cardiac complications due to iron overload. Differential effects on myocardial… Expand
  • figure 1
  • table 1
  • figure 2
Review
2006
Review
2006
For nearly 30 years, patients with transfusional iron overload have depended on nightly deferoxamine infusions for iron chelation… Expand
  • table 1
  • table 2
  • table 3
Highly Cited
2003
Highly Cited
2003
The identification of a safe, orally active iron chelator is critically important for the prevention of morbidity and early death… Expand
  • figure 1
  • figure 2
  • figure 3
  • table 1
Highly Cited
2002
Highly Cited
2002
BACKGROUND Despite the introduction of the parenteral iron chelator desferrioxamine more than 30 years ago, 50% of patients with… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Review
1997
Review
1997
Iron-chelating therapy with deferoxamine in patients with thalassemia major has dramatically altered the prognosis of this… Expand
Highly Cited
1995
Highly Cited
1995
BACKGROUND To determine whether the orally active iron chelator deferiprone (1,2-dimethyl-3-hydroxy-pyridin-4-one) is efficacious… Expand